Brief: Sensei Biotherapeutics Announces Clinical Supply Agreement With Regeneron For Phase 1/2 Clinical Trial Evaluating SNS-101

Faeth Therapeutics,

05/01/2023 15:57

Jan 5 (Reuters) - Sensei Biotherapeutics Inc  SNSE.O :
    * SENSEI BIOTHERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT
WITH
REGENERON FOR PHASE 1/2 CLINICAL TRIAL EVALUATING SNS-101, A
CONDITIONALLY ACTIVE VISTA-BLOCKING ANTIBODY, IN COMBINATION
WITH LIBTAYO® (CEMIPLIMAB) IN SOLID TUMORS
    * SENSEI BIOTHERAPEUTICS INC - UNDER TERMS OF AGREEMENT,
SENSEI
WILL SPONSOR AND FUND PLANNED CLINICAL TRIAL AND REGENERON WILL
PROVIDE LIBTAYO®
    * SENSEI BIOTHERAPEUTICS INC - WILL MAINTAIN GLOBAL
DEVELOPMENT
AND COMMERCIAL RIGHTS TO SNS-101
    * SENSEI BIOTHERAPEUTICS INC - SNS-101 IS CURRENTLY UNDER
PRECLINICAL DEVELOPMENT
    * SENSEI BIOTHERAPEUTICS INC - SAFETY AND EFFICACY OF
SNS-101 OR
ITS ADMINISTRATION WITH LIBTAYO® HAVE NOT BEEN REVIEWED BY ANY
REGULATORY AUTHORITIES
    * SENSEI BIOTHERAPEUTICS INC - ON TRACK TO SUBMIT AN
INVESTIGATIONAL NEW DRUG APPLICATION FOR SNS-101 IN OR BEFORE
APRIL 2023
    * SENSEI BIOTHERAPEUTICS INC - FOR PHASE 1/2 CLINICAL TRIAL
SNS-101 IS EXPECTED TO COMMENCE IN 2023 PENDING REGULATORY
CLEARANCE

Source text for Eikon:  ID:nGNX1hVQnN 
Further company coverage:  SNSE.O 
 ((Reuters.Briefs@thomsonreuters.com;))